Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?
Abbott is down nearly 23% this year while Pfizer dangles a 7% yield, and both just beat Q1 estimates. One of these discounts is a genuine buying opportunity and the other is a slow-moving trap waiting to spring.
Abbott Laboratories (NYSE: ABT | ABT Price Prediction) and Pfizer (NYSE: PFE) both delivered Q1 2026 beats, yet the market treats them differently. Abbott is down 22.99% year to date after a medtech correction. Pfizer sits flat, propped up by a 7.14% yield. Which discount is real, and which is a trap?
Devices Carry Abbott. Oncology Props Up Pfizer.
Abbott’s Q1 revenue hit $11.16B, with Medical Devices up +13.2% to $5.54B. FreeStyle Libre alone did $2.08B, up 13.8%. Nutrition fell 6%, but the $21B Exact Sciences deal closed March 23, 2026, adding Cologuard and Cancerguard to a fast-growing diagnostics franchise. CEO Robert Ford called the quarter “aligned with our expectations”.
Pfizer posted $14.45B in revenue, with Oncology up 9% to $3.83B and Padcev surging 39%. Eliquis added 13%. COVID revenue continued eroding: Comirnaty fell 59%, Paxlovid dropped 62%. Albert Bourla framed 2026 as a “defining period”, leaning on oncology and obesity.
A Compounder Meets a Turnaround
Abbott trades at a forward 17x earnings after the correction, with analysts targeting $116.72. Pfizer is cheaper on paper at a forward 8x, though its PEG sits at 2.815.
| Lens | Abbott | Pfizer |
| Core Bet | Diabetes devices, cancer diagnostics | Oncology, obesity, GLP-1 |
| Dividend | 54 straight years of hikes | 7.14% yield, no buybacks in 2026 |
| Key Vulnerability | Exact Sciences dilution, FX | Patent cliffs, tariff and MFN pricing risk |
Insider buying signals confidence. Abbott’s CFO Philip Boudreau bought 11,109 shares on April 23, 2026 near $92, and Director Daniel Starks added 10,000 shares.
The Next Test Is Pipeline Delivery
Abbott must absorb the $0.20 Exact Sciences dilution while hitting the $5.38 to $5.58 full-year EPS range. Libre attach rates in Type 2 basal-insulin patients, backed by a 0.6% HbA1c reduction in the FreeDM2 trial, signal growth potential.
For Pfizer, Metsera obesity assets and roughly 20 pivotal 2026 studies must convert. Generic headwinds are real, and Most-Favored-Nation pricing plus tariff exposure make the $1.5B EPS guide fragile.
Why I Lean Toward Abbott at This Discount
Pfizer’s 8x multiple and yield look tempting, but the setup screens as a value trap. COVID revenue is deflating, patent losses cost another $1.5B this year, and buybacks are paused. You are being paid to wait on a pipeline that has not proven itself.
Abbott, priced at a 16x forward multiple after the drawdown, feels cleaner. A 54-year dividend streak, medtech growth compounding at double digits, and insiders buying on the way down make it the better defensive play. If oncology and obesity readouts light up later this year, I will reconsider Pfizer. Until then, Abbott screens as the stronger risk-adjusted setup.
Contact [email protected] for any questions or corrections.
Alex Sirois is a financial writer with experience spanning both retail and institutional investing. He has written for InvestorPlace and held roles at BNY Mellon and Bernstein, giving him a perspective that bridges Main Street portfolios and Wall Street analysis.
Alex holds an MBA from George Washington University and has built his career across multiple industries, including e-commerce, education, and translation — a breadth of experience that informs how he breaks down complex financial topics for everyday investors. His writing is conversational, actionable, and grounded in long-term, buy-and-hold investing principles.
At 247 Wall St., Alex focuses on delivering analysis that is both accessible and useful, with a clear emphasis on helping readers make more informed decisions with their money.
